Hematologic Malignancy
Adult Acute Lymphoblastic Leukemia
CI-CAN-00001706Explore in graph →
Hematologic44 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001706Explore in graph →
Clinical trials
249 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (37)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05909059 | CAR T-cell Therapy in Patients With Renal Dysfunction | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03938987 |
| Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)(ACIT001/EXC002) |
| recruiting |
| Phase 1 / Phase 2 |
| 63 |
| University of AlbertaOTHER |
| 1 |
| Feb 9, 2026 |
| clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07059156 | Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL | recruiting | Phase 2 / Phase 3 | 50 | Shanxi Bethune HospitalOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06557161 | A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL | recruiting | Phase 2 | 170 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06564545 | A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL | recruiting | Phase 2 | 276 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06250959 | RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.(BEAT-ALL-2024) | recruiting | Phase 2 | 124 | Chen SuningOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06220487 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL(ABC) | recruiting | Phase 2 | 67 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 30, 2026source: clinicaltrials